Multiple Myeloma: Therapeutic and Management Strategies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 20 January 2026 | Viewed by 563
Special Issue Editor
Special Issue Information
Dear Colleagues,
The treatment landscape of multiple myeloma has changed over the past several years with the development and approval of several new therapies. Therapies including CD38 monoclonal antibodies and immunotherapy in the form of both CAR T and bispecific T cell engagers have changed the management of relapsed and refractory multiple myeloma. Despite these new therapies, multiple myeloma is still considered to be an incurable hematologic malignancy. Recent and ongoing clinical trials have evaluated these therapies in earlier lines and looked to define the optimal sequencing of treatments.
For example, CD38 antibodies have been used in combinations in both transplant eligible and ineligible patients in the frontline setting resulting in improved efficacy. This shift in management, in turn, has altered second-line treatment and beyond. As more patients are treated with immunotherapies earlier in their disease course, the management and prevention of complications related to treatment needs to be considered in the overall management of multiple myeloma.
This Special Issue will address the most recent and relevant scientific findings regarding frontline treatment, treatment of relapsed refractory multiple myeloma, and optimal sequencing of therapies. In addition, the Special Issue will also address the management of toxicities specific to these emerging treatments.
Dr. Terri Parker
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- frontline treatment
- monoclonal antibodies
- sequencing of treatment
- immunotherapy
- CAR T
- Bi-specific T cell engagers
- toxicity management
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
